Pricing Log in Create free account

COSCIENS Biopharma Inc. (CSCIF) vs IMMURON (IMRN)

COSCIENS Biopharma Inc. and IMMURON are both Biotechnology companies. COSCIENS Biopharma Inc. and IMMURON are of similar size ($8.6M and $8.3M). IMMURON has negative trailing earnings, so its P/E is not meaningful; COSCIENS Biopharma Inc. trades at 1.0×. COSCIENS Biopharma Inc. grew revenue faster over the last twelve months: −3.02% against −6.62%. COSCIENS Biopharma Inc. has the higher net margin (75.1% vs −262.7%) and the lower return on invested capital (−40.6% vs 0.00%). Across the 15 metrics below, IMMURON leads on 8 and COSCIENS Biopharma Inc. on 7.

Valuation

Metric CSCIF IMRN Biotechnology median
P/E 1.03 n/m 8.50
P/S 0.78 n/m 9.71
P/B 0.46 n/m 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m 0.93 0.64
EV/Sales 0.17 (3.47) 9.21
Earnings yield 96.93% (2.10%) (33.15%)
Free cash flow yield (45.48%) 0.00% (25.50%)

Profitability

Metric CSCIF IMRN Biotechnology median
Gross margin 46.48% 71.28% 65.16%
Operating margin (71.13%) 0.00% 0.00%
Net margin 75.11% (262.71%) 0.00%
Free cash flow margin (40.36%) 0.00% 0.00%
Return on equity 59.74% 0.00% (56.36%)
Return on assets 28.24% 0.00% (48.04%)
Return on invested capital (40.56%) 0.00% 0.00%

Growth

Metric CSCIF IMRN Biotechnology median
Revenue growth (TTM) (3.02%) (6.62%) 6.02%
EPS growth (last fiscal year) 44.86% 37.29% 30.26%
Revenue growth, 5-year CAGR 15.47% 116.96% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CSCIF IMRN Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 4.33 7.17 4.72
Net debt to EBITDA 0.78 1.81 0.96

Dividend

Metric CSCIF IMRN Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric CSCIF IMRN Biotechnology median
Market cap 8.57m 8.31m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack